Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunomodulators and the complement system.

M Kondo, H Kato, T Yoshikawa

    Methods and Findings in Experimental and Clinical Pharmacology
    |February 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Adenosine A2 receptor antagonist facilitates the reversal of long-term potentiation (depotentiation) of evoked postsynaptic potentials but inhibits that of population spikes in hippocampal CA1 neurons.

    Neuroscience letters·1992
    Same author

    The helix-loop-helix/leucine repeat transcription factor USF can be functionally regulated in a redox-dependent manner.

    The Journal of biological chemistry·1992
    Same author

    Immunohistochemical study of the histogenesis of esophageal carcinosarcoma.

    Japanese journal of clinical oncology·1992
    Same author

    Structure and distribution of the lymphatic vessels in the parietal pleura of the monkey as studied by enzyme-histochemistry and by light and electron microscopy.

    Archives of histology and cytology·1992
    Same author

    Specific expressions of Fyn and Lyn, lymphocyte antigen receptor-associated tyrosine kinases, in the central nervous system.

    Brain research. Molecular brain research·1992
    Same author

    A hyperpolarizing response induced by glutamate in mouse cerebellar Purkinje cells.

    Neuroscience research·1992
    Same journal

    [Proceedings of the XVIII TASPE Seminar, Granada, Spain, 4-5 February 2010].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Treatment algorithm for gastrointestinal graft-versus-host disease].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Classification of chronic graft-versus-host disease].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Pegfilgrastim in hematopoietic stem cell transplantation].

    Methods and findings in experimental and clinical pharmacology·2011
    Same journal

    [Allogeneic transplantation in multiple myeloma patients: results and recommendations in February 2010].

    Methods and findings in experimental and clinical pharmacology·2011
    See all related articles

    Immunomodulators activate the complement system, enhancing the host defense against cancer. This immune response involves complement-derived factors that destroy tumor cells, highlighting the complement system

    Area of Science:

    • Immunology
    • Oncology
    • Complement System Biology

    Background:

    • Immunomodulators are increasingly studied for their potential in cancer treatment.
    • The complement system is a crucial part of the innate immune response.
    • Its role in anti-neoplasm host defense warrants further investigation.

    Purpose of the Study:

    • To explore the role of the complement system in host defense against neoplasm when modulated by immunomodulators.
    • To elucidate the mechanisms by which immunomodulators influence the complement system and its anti-tumor effects.

    Main Methods:

    • In vitro and in vivo studies assessing complement activation by immunomodulators.
    • Analysis of serum complement levels and binding to tumor cells post-immunomodulator administration.

    Related Experiment Videos

  • Evaluation of the generation of complement-derived chemotactic factors (C3a, C5a) and their effect on polymorphonuclear leukocytes (PMNs) in ascites.

    • Main Results:

    • Most immunomodulators activate the complement system in vitro via classical or alternative pathways.
    • Systemic immunomodulator administration activates complement, elevates serum complement levels, and can bind complement to tumor cells.
    • Activated complement, via C3a and C5a, promotes PMN accumulation and tumor cell destruction in ascites, demonstrating an anti-tumor effect.

    Conclusions:

    • The complement system plays a significant role in the host-defense mechanism against neoplasm.
    • Immunomodulator-induced complement activation and subsequent generation of chemotactic factors contribute to anti-tumor immunity.
    • Targeting the complement system with immunomodulators represents a promising strategy in cancer therapy.